What is basiliximab, and what is it used for?
Basiliximab is a medicine used to help prevent organ rejection in people who receive a kidney transplant. It works by blocking a specific immune signal required for T-cell activation, which reduces the body’s attack on the transplanted kidney [1].
How does basiliximab work in transplant patients?
After a transplant, the immune system can become activated and attack the new organ. Basiliximab targets the IL-2 receptor (CD25) on activated T cells, helping prevent the proliferation of these immune cells and lowering the risk of rejection [1].
How is basiliximab given during kidney transplantation?
Basiliximab is administered as an intravenous (IV) infusion as part of the transplant regimen. It is typically used together with other immunosuppressive medicines (commonly including a calcineurin inhibitor and corticosteroids) rather than as the only rejection-prevention drug [1].
When is basiliximab used—what patients are eligible?
Basiliximab is used for patients receiving kidney transplants to reduce the risk of acute rejection. It is not intended to treat rejection once it has already occurred; it is used for prevention as part of the initial post-transplant immunosuppression plan [1].
What side effects do people associate with basiliximab?
As an immunosuppressive therapy, basiliximab can increase the risk of infections and may cause infusion-related or other adverse reactions. The full side-effect profile depends on the overall transplant medication regimen the patient receives alongside basiliximab [1].
What are the alternatives to basiliximab?
In kidney transplantation, basiliximab is one option for prevention of rejection. Other immunosuppressive strategies may include different IL-2 receptor–targeting approaches or antibody therapies that act through other immune pathways, depending on the transplant center and patient risk factors [1].
Is basiliximab related to other transplant biologics?
Basiliximab is an antibody designed specifically to block the IL-2 receptor (CD25) on T cells. Other transplant biologics use different targets and mechanisms, which can affect when they’re used (induction versus treatment), intensity, and side-effect patterns [1].
Sources
[1] https://www.drugs.com/basiliximab.html